Uganda program aims to stop heart disease in its tracks
NCT ID NCT05783375
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at a program called ADUNU, which aims to find and treat people with rheumatic heart disease in two districts of Uganda. The program uses portable ultrasound to screen for the disease and a registry to keep patients on preventive medication. Researchers will check how many people are reached, stay in care, and follow treatment, as well as the program's costs and how well it works in real-world clinics.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this program could improve screening and treatment adherence for rheumatic heart disease in Uganda, reducing complications and deaths.
- What could go wrong
- This is an observational study, not a clinical trial of a new drug or device. Results may not apply to other regions or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 221 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * residing in one of two involved districts in Uganda * providers at HCIIIs and HCIVs located in one of two involved Ugandan districts Exclusion Criteria: * None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rheumatic heart disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Uganda Heart Institute
RECRUITINGKampala, Uganda, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The clotting test that could reshape warfarin care in egypt
- Shock waves for stiff heart valves: new balloon tested in First-in-Human trial
- Can community hospitals in zambia master severe disease care?
- Could a monthly pill replace painful penicillin shots for rheumatic heart disease?
- New registry tool aims to stop heart patients from falling through the cracks
- AI could revolutionize heart disease screening in poor regions